BriaCell Therapeutics Corp. reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell?s Bria-IMT? regimen: patients that have developed resistance to (and failed to respond to) Antibody-Drug Conjugates (?ADC?, ?ADCs?).

ADCs have significantly advanced cancer therapy in the past few years; however many patients experience serious side effects and others develop resistance to ADCs; therefore, their medical needs remain unmet. BriaCell Clinical Data in ADC Refractory Patients: Bria-IMT? Combined with an Immune Check Point Inhibitor: In a subset of BriaCell?s ongoing Phase 2 study, clinical data of 23 advanced metastatic breast cancer patients who failed prior treatments with ADCs were analyzed.

Four patients had prior treatments with KADCYLA®; 13 had prior treatments with ENHERTU®, 13 with TRODELVY®, of which 7 of these patients were treated with multiple agents (totaling 23 patients). In addition, 7 of these 23 patients had also failed prior treatment with immune checkpoint inhibitors. Heavily pre-treated metastatic breast cancer patients had a median number of 6 prior treatments.

Kaplan-Meier analysis showed median overall survival (OS) that was up to twice that reported in the literature, with some patients recording survival of over a year. Disease control rate of 40% was observed in evaluable patients further indicating clinical benefit. Progression free survival (PFS) was similar or better than that of the patients?

prior therapy in 40% of patients, highlighting clinical benefit and tolerability of the Bria-IMT? regimen. 17 of 23 patients remain alive as of today, suggesting efficacy, tolerability, and survival benefit of BriaCell?s Bria-IMT?

regimen. The data will continue to mature as patients remain on the study. All patients received BriaCell?s therapy with no toxicity related discontinuations.

Importantly, there were no cases of Interstitial Lung Disease (ILD) with Bria-IMT? ? a well-documented serious side effect of ADCs.